AI Article Synopsis

Article Abstract

Introduction: Yellow fever is a serious illness public health importance and is transmitted by mosquitoes of the genera Haemagogus and Sabethes in the rural and forest environments, and by Aedes aegypti in the urban setting. In Colombia, Haemagogus janthinomys and H. equinus are considered efficient vectors of this viral disease.

Objective: The presence of the mosquito Haemagogus equinus was recorded over an 8 year period, in the periurban areas of the Soledad and Malambo municipalities (Atlantico Province) of northern Colombia.

Materials And Methods: The data was obtained from records of the entomological collections from two collection sites: (1) 14 larva traps located at the Erneasto Cortissoz airport in the municipality of Soledad between 1997--2005 and (2) 10 larva traps located at Vergara and Velasco Batallion in the municipality of Malambo in 2005.

Results: Haemogogus equinus was reported for the first time in Soledad in 1998. In the following 8 years, 197 larvae were reported. The individuals were found sharing the trap with Aedes aegypti, Culex nigripalpus and Uranotaenia lowii. In Malambo, the first discovery of H.equinus occurred in 2005, with a total of 641 larvae. No other Culicidae were associated with it.

Conclusion: The presence of H. equinus in larvitraps located near the urban zone, shows adaptation to the use of artificial containers as larval habitats, Urbanization of this species in zones with a high Ae. aegypti infestation index increases the potential introduction of sylvan yellow fever virus and constitutes a risk for re-emergence of urban cycles of yellow fever.

Download full-text PDF

Source

Publication Analysis

Top Keywords

yellow fever
12
haemagogus equinus
8
soledad malambo
8
aedes aegypti
8
larva traps
8
traps located
8
equinus
5
[presence haemagogus
4
equinus theobald
4
theobald 1903
4

Similar Publications

Between October 2021 and February 2022, there was an outbreak of Yellow fever that spread within several districts in the northern part of Ghana. Febrile illnesses such as Yellow fever are often misdiagnosed as malaria and vice versa, which delays appropriate management and treatment. Hence, the true burden of Yellow fever and malaria are mostly underestimated.

View Article and Find Full Text PDF

The Chikungunya virus (CHIKV) presents substantial public health challenges in the Eastern Mediterranean Region (EMR), with its prevalence and interaction with other arboviruses (ABVs) remaining poorly understood. This systematic review and meta-analysis aimed to assess the prevalence of CHIKV and its association with other ABVs, such as dengue virus (DENV), Rift Valley fever virus (RVFV), malaria, and yellow fever virus (YFV), in the EMR. We systematically searched databases including PubMed, Embase, Web of Science, Scopus, Cochrane Library, CINAHL, PsycINFO, and ScienceDirect to identify epidemiological studies that report CHIKV prevalence and provide odds ratios (ORs) for CHIKV compared to other ABVs.

View Article and Find Full Text PDF

Aedes-borne arboviral human infections in Europe from 2000-2023: a systematic review and meta-analysis.

Travel Med Infect Dis

January 2025

University of Zürich, Epidemiology, Biostatistics and Prevention Institute, Hirschengraben 84, 8001, Zürich, Switzerland; WHO Collaborating Centre for Travellers' Health, Department of Global and Public Health, MilMedBiol Competence Centre, Hirschengraben 84, 8001, Zürich, Switzerland.

Introduction: Aedes-borne arboviral infections, both imported and autochthonous, are reported in Europe. We evaluated the landscape of these infections in Europe over 23 years and attempted to pre-empt the trajectory of impact of these infections in the climatic context of Aedes mosquito expansion in Europe.

Methods: This systematic review was conducted in accordance with PRISMA guidelines and registered in Prospero (CRD42023360259).

View Article and Find Full Text PDF

Immunogenicity of yellow fever vaccine co-administered with 13-valent pneumococcal conjugate vaccine in rural Gambia: A cluster-randomised trial.

Vaccine

January 2025

Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, Banjul, the Gambia; Department of Disease Control, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK; Murdoch Children's Research Institute, Melbourne, Australia; Department of Paediatrics, University of Melbourne, Australia.

Introduction: Because booster doses of pneumococcal conjugate vaccine (PCV) may be given at a similar time to yellow fever vaccine (YF), it is important to assess the immune response to YF when co-administered with PCV. This has been investigated during a reduced-dose PCV trial in The Gambia.

Methods: In this phase 4, parallel-group, cluster-randomized trial, healthy infants aged 0-10 weeks were randomly allocated to receive either a two-dose schedule of PCV13 with a booster dose co-administered with YF vaccine at age 9 months (1 + 1 co-administration) or YF vaccine administered separately at age 10 months (1 + 1 separate) or the standard three early doses of PCV13 with YF vaccine at age 9 months (3 + 0 separate).

View Article and Find Full Text PDF

T cells have been identified as correlates of protection in viral infections. However, the level of vaccine-induced T cells needed and the extent to which they alone can control acute viral infection in humans remain uncertain. Here we conducted a double-blind, randomized controlled trial involving vaccination and challenge in 33 adult human volunteers, using the live-attenuated yellow fever (YF17D) and chimeric Japanese encephalitis-YF17D (JE/YF17D) vaccines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!